A Randomized, Double Blind, Third Party Open, Placebo Controlled Multi-center Study Of Efficacy, Safety And Tolerability Of Pf-06743649 In Gout Subjects

Baseline of Serum Uric Acid

时间窗: Baseline (pre-dose Day 1)

An elevation in serum uric acid, hyperuricemia, is a prerequisite for the development of gout.

Percent Change From Baseline in Serum Uric Acid Level at 24 Hours Post Dose on Day 14

时间窗: Day 14 Hour 24

Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

时间窗: Baseline up to 28 days after last study drug administration (Day 42)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state AEs included both serious and non-serious events.

Number of Participants With Laboratory Test Abnormalities

时间窗: Baseline up to follow up visit (Day 25-29)

Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters include hematology (Hemoglobin, Hematocrit, red blood cell \[RBC\] count, Platelet count, mean corpuscular volume \[MCV\], mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration \[MCHC\], white blood cell \[WBC\] count, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes), hematocrit (blood urea nitrogen \[BUN\]/urea and Creatinine, Glucose , Calcium, Sodium, Potassium, Chloride, Total CO2 \[Bicarbonate\], aspartate transaminase \[AST\], alanine transaminase \[ALT\], Total Bilirubin, Alkaline phosphatase, Albumin, Total protein, Thyroid Stimulating Hormone \[TSH\], free T3 \[FT3\] and free T4 \[FT4\] ), urinalysis (pH, Glucose \[qual\], Protein, Blood, Ketones, Nitrites, Leukocyte esterase, Urobilinogen, Urine bilirubin, Microscopy \[including crystals\]) and other (follicle-stimulating hormone \[FSH\], Urine drug screen).

Number of Participants With Potentially Clinically Significant Vital Signs Findings

时间窗: Baseline up to follow up visit (Day 25-29)

Criteria for potential clinically important change in vital signs included: Systolic blood pressure (BP) less than (\<) 90 millimeters of mercury (mmHg) or more than or equal to (\>=)30 mmHg change from baseline, diastolic BP of \<50 mmHg or \>=20 mmHg change from baseline, Supine pulse rate of \<40 or more than (\>)120 beats per minute (bpm).

Number of Participants With Electrocardiogram (ECG) Values Meeting Categorical Summarization Criteria

时间窗: Baseline up to Day 16

Criteria for potential clinically important changes in ECG (12-lead) were defined as: the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval) \>=300 milliseconds (msec) or increase from baseline \>=25% when baseline \>200 msec or increase from baseline \>=50% when baseline less than or equal to (\<=) 200 msec; time from the beginning of the electrocardiogram Q wave to the end of the S wave corresponding to ventricular depolarization (QRS) interval \>=140 msec or \>=50% increase from baseline; the beginning of the Q wave to the end of the T wave corresponding to electrical systole (QT) interval corrected using the Fridericia formula (QTcF) of 450 to \< 480 msec, 480 to \<500 msec and \>=500 msec, or an increase of 30 to \<60 msec or \>=60 msec from baseline.